These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31199580)

  • 1. NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
    Tlemsani C; Pécuchet N; Gruber A; Laurendeau I; Danel C; Riquet M; Le Pimpec-Barthes F; Fabre E; Mansuet-Lupo A; Damotte D; Alifano M; Luscan A; Rousseau B; Vidaud D; Varin J; Parfait B; Bieche I; Leroy K; Laurent-Puig P; Terris B; Blons H; Vidaud M; Pasmant E
    Cancer Med; 2019 Aug; 8(9):4330-4337. PubMed ID: 31199580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Pan Y; Yuan C; Cheng C; Zhang Y; Ma Y; Zheng D; Zheng S; Li Y; Jin Y; Sun Y; Chen H
    Int J Cancer; 2019 Jan; 144(2):290-296. PubMed ID: 30230541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
    Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
    Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
    Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
    BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
    Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
    Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
    Bowman L; Tiu R; Smyth EN; Willard MD; Li L; Beyrer J; Han Y; Singh A
    Clin Lung Cancer; 2021 Jan; 22(1):32-41.e1. PubMed ID: 33221173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
    Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
    Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation sequencing in lung cancer: An initial experience from India.
    Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
    Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Hayashi T; Desmeules P; Smith RS; Drilon A; Somwar R; Ladanyi M
    Clin Cancer Res; 2018 Mar; 24(6):1436-1447. PubMed ID: 29127119
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
    Tønnesen E; Lade-Keller J; Stougaard M
    Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Wang X; Min S; Liu H; Wu N; Liu X; Wang T; Li W; Shen Y; Wang H; Qian Z; Xu H; Zhao C; Chen Y
    EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31036704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
    Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.
    Li W; Qiu T; Ling Y; Gao S; Ying J
    Mol Oncol; 2018 May; 12(5):677-689. PubMed ID: 29518290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
    Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
    Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC;
    PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
    Arcila ME; Drilon A; Sylvester BE; Lovly CM; Borsu L; Reva B; Kris MG; Solit DB; Ladanyi M
    Clin Cancer Res; 2015 Apr; 21(8):1935-43. PubMed ID: 25351745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
    Preusser M; Berghoff AS; Koller R; Zielinski CC; Hainfellner JA; Liebmann-Reindl S; Popitsch N; Geier CB; Streubel B; Birner P
    Eur J Cancer; 2015 Sep; 51(13):1803-11. PubMed ID: 26164066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.